Dr Ulrich Müller

Ulrich Müller

University position


Dr Ulrich Müller is pleased to consider applications from prospective PhD students.


Department of Psychology


Behavioural and Clinical Neuroscience Institute



Research Themes

Cognitive and Behavioural Neuroscience

Clinical and Veterinary Neuroscience


My major research interest is the neurotransmitter modulation of cognitive and emotional processes, with a focus on the role of dopamine and noradrenaline in frontostriatal functions. I use fMRI, radioligand imaging with PET, pharmacological challenges and genetic testing for neurotransmitter polymorphisms in combination with working memory and other prefrontal tasks in healthy volunteers and patients with attention deficit hyperactivity disorder (ADHD), schizophrenia and other neuropsychiatric diseases. The aim of this research is to develop pharmacological and behavioural strategies to improve cognitive functions in patients with ADHD and schizophrenia.

I am a honorary consultant psychiatrist with Cambridgeshire and Peterborough NHS Foundation Trust and director of the Adult ADHD Research Clinic.

Research Focus



working memory




Clinical conditions

Attention deficit hyperactivity disorder

Cognitive impairment



Magnetic resonance imaging (MRI)

Neuropsychological testing

Positron Emission Tomography (PET)



Ed Bullmore

Sam Chamberlain

Luke Clark

Chris Dodds

Peter Jones

Trevor Robbins

Barbara Sahakian

United Kingdom

Jonathan Roiser Web: http://www.ion.ucl.ac.uk/


Roshan Cools Web: http://www.roshancools.com/

Hesse Swen Web: http://www.uni-leipzig.de/english...

Associated News Items

    Key publications

    Del Campo N, Fryer TD, Hong YT, Smith R, Brichard L, Acosta-Cabronero J, Chamberlain SR, Tait R, Izquierdo D, Regenthal R, Dowson J, Suckling J, Baron JC, Aigbirhio FI, Robbins TW, Sahakian BJ, Müller U (2013), “A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment.” Brain 136(Pt 11):3252-70 Details

    Seixas M, Weiss M, Müller U (2012), “Systematic review of national and international guidelines on attention-deficit hyperactivity disorder.” J Psychopharmacol 26(6):753-65 Details

    Dodds CM, Müller U, Clark L, van Loon A, Cools R, Robbins TW (2008), “Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning.” J Neurosci 28(23):5976-82 PDF Details

    Chamberlain SR, Müller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ (2006), “Neurochemical modulation of response inhibition and probabilistic learning in humans.” Science 311(5762):861-3 PDF Details

    Müller U, Steffenhagen N, Regenthal R, Bublak P (2004), “Effects of modafinil on working memory processes in humans.” Psychopharmacology (Berl) 177(1-2):161-9 Details



    Bolea-Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, Heal D, Müller U, Nash J, Santosh P, Sayal K, Sonuga-Barke E, Young SJ, Consensus Group (2014), “Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology.” J Psychopharmacol 28(3):179-203 Details

    Clark-Elford R, Nathan PJ, Auyeung B, Voon V, Sule A, Müller U, Dudas R, Sahakian BJ, Phan KL, Baron-Cohen S (2014), “The effects of oxytocin on social reward learning in humans.” Int J Neuropsychopharmacol 17(2):199-209 Details

    Eisenegger C, Naef M, Linssen A, Clark L, Gandamaneni PK, Müller U, Robbins T (2014), “Role of Dopamine D2 Receptors in Human Reinforcement Learning.” Neuropsychopharmacology Details

    Ellison-Wright I, Nathan PJ, Bullmore ET, Zaman R, Dudas RB, Agius M, Fernandez-Egea E, Müller U, Dodds CM, Forde NJ, Scanlon C, Leemans A, McDonald C, Cannon DM (2014), “Distribution of tract deficits in schizophrenia.” BMC Psychiatry 14(1):99 Details

    Ioannidis K, Chamberlain SR, Müller U (2014), “Ostracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder - was this a correct decision? A literature review.” J Psychopharmacol Details

    Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, Sahakian BJ, Robbins TW (2014), “Targeting impulsivity in Parkinson's disease using atomoxetine.” Brain 137(Pt 7):1986-97 Details

    Morein-Zamir S, Dodds C, van Hartevelt TJ, Schwarzkopf W, Sahakian B, Müller U, Robbins T (2014), “Hypoactivation in right inferior frontal cortex is specifically associated with motor response inhibition in adult ADHD.” Hum Brain Mapp Details

    Umemoto A, Lukie CN, Kerns KA, Müller U, Holroyd CB (2014), “Impaired reward processing by anterior cingulate cortex in children with attention deficit hyperactivity disorder.” Cogn Affect Behav Neurosci 14(2):698-714 Details


    Adamou M, Arif M, Asherson P, Aw TC, Bolea B, Coghill D, Guðjónsson G, Halmøy A, Hodgkins P, Müller U, Pitts M, Trakoli A, Williams N, Young S (2013), “Occupational issues of adults with ADHD.” BMC Psychiatry 13(1):59 Details

    Crockett MJ, Apergis-Schoute A, Herrmann B, Lieberman M, Müller U, Robbins TW, Clark L (2013), “Serotonin Modulates Striatal Responses to Fairness and Retaliation in Humans.” J Neurosci 33(8):3505-3513 Details

    Ioannidis K, Serfontein J, Müller U (2013), “Bulimia nervosa patient diagnosed with previously unsuspected ADHD in adulthood: Clinical case report, literature review, and diagnostic challenges.” Int J Eat Disord Details

    Kaser M, Soltesz F, Lawrence P, Miller S, Dodds C, Croft R, Dudas RB, Zaman R, Fernandez-Egea E, Müller U, Dean A, Bullmore ET, Nathan PJ (2013), “Oscillatory underpinnings of mismatch negativity and their relationship with cognitive function in patients with schizophrenia.” PLoS One 8(12):e83255 Details

    Kuhlmei A, Walther B, Becker T, Müller U, Nikolaus T (2013), “Actigraphic daytime activity is reduced in patients with cognitive impairment and apathy.” Eur Psychiatry 28(2):94-7 Details

    Müller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian BJ (2013), “Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers.” Neuropharmacology 64(1):490-5 Details

    Pironti VA, Lai MC, Müller U, Dodds CM, Suckling J, Bullmore ET, Sahakian BJ (2013), “Neuroanatomical Abnormalities and Cognitive Impairments Are Shared by Adults with Attention-Deficit/Hyperactivity Disorder and Their Unaffected First-Degree Relatives.” Biol Psychiatry Details

    Porchet RI, Boekhoudt L, Studer B, Gandamaneni PK, Rani N, Binnamangala S, Müller U, Clark L (2013), “Opioidergic and dopaminergic manipulation of gambling tendencies: a preliminary study in male recreational gamblers.” Front Behav Neurosci 7:138 Details


    Bolea B, Adamou M, Arif M, Asherson P, Gudjonsson G, Müller U, Nutt Dj, Pitts M, Thome J, Young S (2012), “ADHD matures: time for practitioners to do the same?” J Psychopharmacol 26(6):766-70 PDF Details

    Caisley H, Müller U (2012), “Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: A systematic review.” Eur Psychiatry 27(5):343-9 Details

    Coogan AN, Dobrean A, Donev RM, Mateescu L, Müller U, Thome J, Voinescu BI (2012), “Adult attention deficit hyperactivity disorder: translating research into practice.” Atten Defic Hyperact Disord PDF Details

    Del Campo N, Müller U, Sahakian BJ (2012), “Neural and behavioral endophenotypes in ADHD.” Curr Top Behav Neurosci 11:65-91 Details

    Ersche KD, Cumming P, Craig KJ, Müller U, Fineberg NA, Bullmore ET, Robbins TW (2012), “Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine-serotonin interactions?” J Psychopharmacol 26(6):887-90 Details

    Ersche KD, Turton AJ, Chamberlain SR, Müller U, Bullmore ET, Robbins TW (2012), “Cognitive dysfunction and anxious-impulsive personality traits are endophenotypes for drug dependence.” Am J Psychiatry 169(9):926-36 Details

    Magon U, Müller U (2012), “ADHD with comorbid substance use disorder: review of treatment” Advances in Psychiatric Treatment 18: 436-446

    Müller U, Asherson P (2012), “Addressing common misconceptions about attention deficit hyperactivity disorder in adults” Neuropsychiatry 2: 185-188 PDF

    Zaman R, Arif M, Vaze A, Müller U (2012), “Setting up adult ADHD services in the United Kingdom” Cutting Egde Psychiatry in Practice 2: 170-175 PDF


    Blanchard MM, Chamberlain SR, Roiser J, Robbins TW, Müller U (2011), “Effects of two dopamine-modulating genes ( DAT1 9/10 and COMT Val/Met) on n-back working memory performance in healthy volunteers.” Psychol Med 41(3):611-8 Details

    Chamberlain SR, Robbins TW, Winder-Rhodes S, Müller U, Sahakian BJ, Blackwell AD, Barnett JH (2011), “Translational approaches to frontostriatal dysfunction in attention-deficit/hyperactivity disorder using a computerized neuropsychological battery.” Biol Psychiatry 69(12):1192-203 Details

    Costa A, Riedel M, Müller U, Möller HJ, Ettinger U (2011), “Relationship between SLC6A3 genotype and striatal dopamine transporter availability: A meta-analysis of human single photon emission computed tomography studies.” Synapse Details

    Del Campo N, Tait RJ, Acosta-Cabronero J, Hong YT, Izquierdo-Garcia D, Smith R, Aigbirhio FI, Sahakian BJ, Müller U, Robbins TW, Fryer TD (2011), “Quantification of receptor-ligand binding potential in sub-striatal domains using probabilistic and template regions of interest.” Neuroimage 55(1):101-12 Details

    Ersche KD, Roiser JP, Abbott S, Craig KJ, Müller U, Suckling J, Ooi C, Shabbir SS, Clark L, Sahakian BJ, Fineberg NA, Merlo-Pich EV, Robbins TW, Bullmore ET (2011), “Response perseveration in stimulant dependence is associated with striatal dysfunction and can be ameliorated by a D(2/3) receptor agonist.” Biol Psychiatry 70(8):754-62 Details

    Finke K, Schwarzkopf W, Müller U, Frodl T, Müller HJ, Schneider WX, Engel RR, Riedel M, Möller HJ, Hennig-Fast K (2011), “Disentangling the adult attention-deficit hyperactivity disorder endophenotype: Parametric measurement of attention.” J Abnorm Psychol 120(4):890-901 Details

    Valenzuela M, Bartrés-Faz D, Beg F, Fornito A, Merlo-Pich E, Müller U, Ongür D, Toga AW, Yücel M (2011), “Neuroimaging as endpoints in clinical trials: Are we there yet? Perspective from the first Provence workshop.” Mol Psychiatry 16(11):1064-6 Details

    Young SJ, Adamou M, Bolea B, Gudjonsson G, Muller U, Pitts M, Thome J, Asherson P (2011), “The identification and management of ADHD offenders within the criminal justice system: a consensus statement from the UK Adult ADHD Network and criminal justice agencies.” BMC Psychiatry 11(1):32 Details


    Asherson P, Adamou M, Bolea B, Muller U, Morua SD, Pitts M, Thome J, Young S (2010), “Is ADHD a valid diagnosis in adults? Yes.” BMJ 340:c549 Details

    Chamberlain SR, Grant JE, Costa A, Müller U, Sahakian BJ (2010), “Effects of acute modafinil on cognition in trichotillomania.” Psychopharmacology (Berl) 212(4):597-601 Details

    Ersche KD, Bullmore ET, Craig KJ, Shabbir SS, Abbott S, Müller U, Ooi C, Suckling J, Barnes A, Sahakian BJ, Merlo-Pich EV, Robbins TW (2010), “Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence.” Arch Gen Psychiatry 67(6):632-44 Details

    Finke K, Dodds CM, Bublak P, Regenthal R, Baumann F, Manly T, Müller U (2010), “Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study.” Psychopharmacology (Berl) 210(3):317-29 Details

    Lynall ME, Bassett DS, Kerwin R, McKenna PJ, Kitzbichler M, Muller U, Bullmore E (2010), “Functional connectivity and brain networks in schizophrenia.” J Neurosci 30(28):9477-87 PDF Details

    Morein-Zamir S, Craig KJ, Ersche KD, Abbott S, Muller U, Fineberg NA, Bullmore ET, Sahakian BJ, Robbins TW (2010), “Impaired visuospatial associative memory and attention in obsessive compulsive disorder but no evidence for differential dopaminergic modulation.” Psychopharmacology (Berl) 212(3):357-67 Details

    Roesch-Ely D, Pfueller U, Mundt C, Müller U, Weisbrod M (2010), “[Treatment of cognitive deficits in schizophrenia. Part 2: Pharmacological strategies]” Nervenarzt 81(5):564-76 Details

    Winder-Rhodes SE, Chamberlain SR, Idris MI, Robbins TW, Sahakian BJ, Müller U (2010), “Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers.” J Psychopharmacol 24(11):1649-57 Details


    Chamberlain SR, Hampshire A, Müller U, Rubia K, Del Campo N, Craig K, Regenthal R, Suckling J, Roiser JP, Grant JE, Bullmore ET, Robbins TW, Sahakian BJ (2009), “Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study.” Biol Psychiatry 65(7):550-5 Details

    Dodds C, Müller U, Manly T (2009), “Effects of psychostimulants on alertness and spatial bias in healthy participants.” J Cogn Neurosci 21(3):529-37 Details

    Dodds CM, Clark L, Dove A, Regenthal R, Baumann F, Bullmore E, Robbins TW, Müller U (2009), “The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory.” Psychopharmacology (Berl) 207(1):35-45 PDF Details

    Müller U, Roesch-Ely D (2009), “Can we treat cognitive impairment in schizophrenia?” In: Gallhofer B, Eberhard J (eds.) Controversies in Cognition: From Laboratory and Testing to Better Functioning. Lundbeck, Copenhagen, pp 47-59

    Ullsperger M, Müller U (2009), “Pharmakologische Interventionen in der Klinischen Neuropsychologie” In: Sturm H, Herrmann M, Münte T (eds) Lehrbuch der Klinischen Neuropsychologie: Grundlagen, Methoden, Diagnostik, Therapie. 2. Auflage. Spektrum Akademischer Verlag, Heidelberg, pp 843-858


    Chamberlain SR, Menzies LA, Fineberg NA, Del Campo N, Suckling J, Craig K, Müller U, Robbins TW, Bullmore ET, Sahakian BJ (2008), “Grey matter abnormalities in trichotillomania: morphometric magnetic resonance imaging study.” Br J Psychiatry 193(3):216-21 Details

    Müller U (2008), “Pharmacological treatment” In: Cappa SF, Abutalebi J, Démonet J-F, Fletcher P, Garrard P (eds.) Cognitive Neurology: A Clinical Textbook. Oxford University Press, Oxford, pp 475-498

    Müller U, Becker T (2008), “Kognition und Rehabilitation” In: Kircher TT, Gauggel S (eds.) Neuropsychologie der Schizophrenie. Springer, Heidelberg, pp 613-623


    Barnett JH, Jones PB, Robbins TW, Müller U (2007), “Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls.” Mol Psychiatry 12(5):502-9 Details

    Chamberlain SR, Del Campo N, Dowson J, Müller U, Clark L, Robbins TW, Sahakian BJ (2007), “Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.” Biol Psychiatry 62(9):977-84 Details

    Chamberlain SR, Müller U, Cleary S, Robbins TW, Sahakian BJ (2007), “Atomoxetine increases salivary cortisol in healthy volunteers.” J Psychopharmacol 21(5):545-9 Details

    Chamberlain SR, Müller U, Deakin JB, Corlett PR, Dowson J, Cardinal RN, Aitken MR, Robbins TW, Sahakian BJ (2007), “Lack of deleterious effects of buspirone on cognition in healthy male volunteers.” J Psychopharmacol 21(2):210-5 Details

    Roiser JP, Müller U, Clark L, Sahakian BJ (2007), “The effects of acute tryptophan depletion and serotonin transporter polymorphism on emotional processing in memory and attention.” Int J Neuropsychopharmacol 10(4):449-61 Details


    Chamberlain SR, Müller U, Blackwell AD, Robbins TW, Sahakian BJ (2006), “Noradrenergic modulation of working memory and emotional memory in humans.” Psychopharmacology (Berl) 188(4):397-407 Details

    Chamberlain SR, Müller U, Robbins TW, Sahakian BJ (2006), “Neuropharmacological modulation of cognition.” Curr Opin Neurol 19(6):607-12 Details

    Müller U, Czymmek J, Thöne-Otto A, Von Cramon DY (2006), “Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy.” Brain Inj 20(2):157-60 Details

    Müller U, Fletcher PC, Steinberg H (2006), “The origin of pharmacopsychology: Emil Kraepelin's experiments in Leipzig, Dorpat and Heidelberg (1882-1892).” Psychopharmacology (Berl) 184(2):131-8 Details

    Stengler-Wenzke K, Müller U, Barthel H, Angermeyer MC, Sabri O, Hesse S (2006), “Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder.” Neuropsychobiology 53(1):40-5 Details


    Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, Sabri O, Stengler-Wenzke K (2005), “Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder.” Psychiatry Res 140(1):63-72 Details

    Müller U (2005), “Somatische Behandlungsverfahren mit rehabilitativem Charakter” In: Frieboes RM, Zaudig M, Nosper M (eds) Rehabilitation bei psychischen Störungen. Elsevier/Urban & Fischer, München, pp 110-134

    Müller U, Clark L, Lam ML, Moore RM, Murphy CL, Richmond NK, Sandhu RS, Wilkins IA, Menon DK, Sahakian BJ, Robbins TW (2005), “Lack of effects of guanfacine on executive and memory functions in healthy male volunteers.” Psychopharmacology (Berl) 182(2):205-13 Details

    Müller U, Mottweiler E, Bublak P (2005), “Noradrenergic blockade and numeric working memory in humans.” J Psychopharmacol 19(1):21-8 Details

    Müller U, Suckling J, Zelaya F, Honey G, Faessel H, Williams SC, Routledge C, Brown J, Robbins TW, Bullmore ET (2005), “Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes.” Psychopharmacology (Berl) 180(4):624-33 Details

    Müller U, Ullsperger M, Hammerstein E, Sachweh S, Becker T (2005), “Directed forgetting in schizophrenia: prefrontal memory and inhibition deficits.” Eur Arch Psychiatry Clin Neurosci 255(4):251-7 Details

    Müller U, Werheid K, Hammerstein E, Jungmann S, Becker T (2005), “Prefrontal cognitive deficits in patients with schizophrenia treated with atypical or conventional antipsychotics.” Eur Psychiatry 20(1):70-3 Details

    Steinberg H, Müller U (2005), “Emil Kraepelin 1882/83 in Leipzig und seine frühen pharmakopsychologischen Arbeiten im Lichte der aktuellen Forschung” In: Angermeyer M, Steinberg H (eds) 200 Jahre Psychiatrie an der Universität Leipzig: Personen und Konzepte. Springer, Heidelberg, pp 121-154


    Hensel A, Ibach B, Muller U, Kruggel F, Kiefer M, Gertz HJ (2004), “Does the pattern of atrophy of the Corpus callosum differ between patients with frontotemporal dementia and patients with Alzheimer's disease?” Dement Geriatr Cogn Disord 18(1):44-9 Details

    Hesse S, Barthel H, Schwarz J, Sabri O, Müller U (2004), “Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders.” Neurosci Biobehav Rev 28(6):547-63 Details

    Stengler-Wenzke K, Müller U, Angermeyer MC, Sabri O, Hesse S (2004), “Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD).” Eur Arch Psychiatry Clin Neurosci 254(4):252-5 Details


    Hesse S, Barthel H, Murai T, Müller U, Müller D, Seese A, Kluge R, Sabri O (2003), “Is correction for age necessary in neuroimaging studies of the central serotonin transporter?” Eur J Nucl Med Mol Imaging 30(3):427-30 Details

    Müller U, Wolf H, Kiefer M, Gertz HJ (2003), “[A systematic comparison of national and international dementia guidelines]” Fortschr Neurol Psychiatr 71(6):285-95 Details

    Murai T, Barthel H, Berrouschot J, Sorger D, von Cramon DY, Müller U (2003), “Neuroimaging of serotonin transporters in post-stroke pathological crying.” Psychiatry Res 123(3):207-11 Details

    Stengler-Wenzke K, Müller U, Matthes-von-Cramon G (2003), “[Compulsive-obsessive disorder after severe head trauma: diagnosis and treatment]” Psychiatr Prax 30(1):37-9 Details


    Bublak P, Müller U, Grön G, Reuter M, von Cramon DY (2002), “Manipulation of working memory information is impaired in Parkinson's disease and related to working memory capacity.” Neuropsychology 16(4):577-90 Details

    Müller U, Reuter M, Hermann W, Gertz HJ (2002), “[Levodopa dependency in Parkinson's disease: case report and review]” Nervenarzt 73(9):887-91 Details

    Schubert T, Volkmann J, Müller U, Sturm V, Voges J, Freund HJ, Von Cramon DY (2002), “Effects of pallidal deep brain stimulation and levodopa treatment on reaction-time performance in Parkinson's disease.” Exp Brain Res 144(1):8-16 Details

    Stengler-Wenzke K, Müller U (2002), “Fluoxetine for OCD after brain injury.” Am J Psychiatry 159(5):872 Details

    Werheid K, Hoppe C, Thöne A, Müller U, Müngersdorf M, von Cramon DY (2002), “The Adaptive Digit Ordering Test: clinical application, reliability, and validity of a verbal working memory test.” Arch Clin Neuropsychol 17(6):547-65 Details


    Murai T, Müller U, Werheid K, Sorger D, Reuter M, Becker T, von Cramon DY, Barthel H (2001), “In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease.” J Neuropsychiatry Clin Neurosci 13(2):222-8 Details

    Schneider S, Müller U (2001), “[Synaesthesia - towards a cognitive neuroscience of coloured hearing]” Fortschr Neurol Psychiatr 69(11):532-8 Details


    Barthel H, Müller U, Wächter T, Slomka P, Dannenberg C, Murai T, Kahn T, Georgi P (2000), “[Multimodal SPECT and MRT imaging data analysis for an improvement in the diagnosis of idiopathic Parkinson's syndrome]” Radiologe 40(10):863-9 Details

    Hoppe CD, Müller UD, Werheid KD, Thöne AD, von Cramon YD (2000), “Digit Ordering Test: clinical, psychometric, and experimental evaluation of a verbal working memory test.” Clin Neuropsychol 14(1):38-55 Details

    Müller U, Wächter T, Barthel H, Reuter M, von Cramon DY (2000), “Striatal [123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease.” J Neural Transm 107(3):303-19 Details

    Ullsperger M, Mecklinger A, Müller U (2000), “An electrophysiological test of directed forgetting: the role of retrieval inhibition.” J Cogn Neurosci 12(6):924-40 Details


    Frieboes RM, Müller U, Murck H, von Cramon DY, Holsboer F, Steiger A (1999), “Nocturnal hormone secretion and the sleep EEG in patients several months after traumatic brain injury.” J Neuropsychiatry Clin Neurosci 11(3):354-60 Details

    Müller U (1999), “Pharmakologie” In: Frommelt P, Grötzbach H (eds) Neuro-Rehabilitation: Grundlagen, Praxis, Dokumentation. Blackwell, Berlin, pp 541-551

    Müller U, Murai T, Bauer-Wittmund T, von Cramon DY (1999), “Paroxetine versus citalopram treatment of pathological crying after brain injury.” Brain Inj 13(10):805-11 Details


    Becker T, Müller U (1998), “Relevance of brain imaging studies for social psychiatry.” Epidemiol Psichiatr Soc 7(2):89-93 Details

    Müller U, von Cramon DY, Pollmann S (1998), “D1- versus D2-receptor modulation of visuospatial working memory in humans.” J Neurosci 18(7):2720-8 PDF Details

    von Cramon DY, Müller U (1998), “The septal region and memory.” Adv Tech Stand Neurosurg 24:3-40 Details


    Müller U, Frieboes R, von Cramon DY (1996), “Diagnose und Therapie emotionaler Instabilität nach Hirninfarkt” In: Möller HJ, Müller-Spahn F, Kurtz G (eds) Aktuelle Perspektiven der Biologischen Psychiatrie. Springer, Wien, pp 112-116


    Müller U, von Cramon DY (1994), “The therapeutic potential of bromocriptine in neuropsychological rehabilitation of patients with acquired brain damage.” Prog Neuropsychopharmacol Biol Psychiatry 18(7):1103-20 Details


    Weller M, Müller U, Kornhuber J (1992), “Paranoid psychosis, epidermoid tumor, and epilepsy: "symptomatic" psychosis or coincidence?” J Clin Psychiatry 53(7):257-8 Details


    Lesch KP, Müller U, Rupprecht R, Kruse K, Schulte HM (1989), “Endocrine responses to growth hormone-releasing hormone, thyrotropin-releasing hormone and corticotropin-releasing hormone in depression.” Acta Psychiatr Scand 79(6):597-602 Details

    Rupprecht R, Lesch KP, Müller U, Beck G, Beckmann H, Schulte HM (1989), “Blunted adrenocorticotropin but normal beta-endorphin release after human corticotropin-releasing hormone administration in depression.” J Clin Endocrinol Metab 69(3):600-3 Details